DCTD Programs
Last Updated: 12/19/2024
Apply for Grants
The Division of Cancer Treatment and Diagnosis funds a large portfolio of grants and contracts. Here we provide a listing of funding opportunities that are accepting applications. Please visit this page regularly for updates.
**Important DCTD Grantsmanship Resources**
Awaiting Receipt of Applications (ARAs) for Large Budget Grant Applications
Program Project (P01) Grant Development Guidance for Investigators Interested in DCTD Research Areas
Funding Opportunities through DCTD’s Programs
Visit the websites of DCTD's individual programs for more information on available funding opportunities.
- Cancer Diagnosis Program
- Cancer Imaging Program
- Cancer Therapy Evaluation Program
- Developmental Therapeutics Program
- Radiation Research Program
- Translational Research Program
- Office of Cancer Complementary and Alternative Medicine
| Title | Announcement Number | Expiration Date | Activity Code |
|---|---|---|---|
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (Clinical Trial Not Allowed) | PAR-22-090 | January 8, 2025 | R21 |
| Exploratory/Developmental Bioengineering Research Grants (EBRG) (Clinical Trial Optional) | PAR-22-091 | January 8, 2025 | R21 |
| Bioengineering Partnerships with Industry (U01 Clinical Trial Optional) | PAR-22-123 | January 8, 2025 | U01 |
| Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) | PAR-22-114 | January 24, 2025 | Admin Suppl |
| NCI National Clinical Trials Network | RFA-CA-24-030 Companion Notices: RFA-CA-24-031 RFA-CA-24-032 RFA-CA-24-033 RFA-CA-24-034 RFA-CA-24-035 |
February 25, 2025 | U10 |
| Innovative Research in Cancer Nanotechnology (IRCN; Clinical Trial Not Allowed) | PAR-25-106 | April 5, 2025 | R01 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) | PAR-25-171 | May 8, 2025 | R01 |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (Clinical Trial Not Allowed) | PAR-25-108 | May 8, 2025 | R21 |
| Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (Clinical Trial Not Allowed) | PAR-25-107 | May 8, 2025 | R01 |
| Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (Clinical Trial Not Allowed) | PA-25-174 | May 8, 2025 | R01 |
| Systematic Testing of Radionuclides in Preclinical Experiments (Clinical Trial Not Allowed) | PA-25-173 | May 8, 2025 | R21 |
| NCI Clinical and Translational Exploratory/Developmental Studies (Clinical Trial Optional) | PAR-25-139 | July 2, 2025 | R21 |
| Imaging, biomarkers and digital pathomics for the early detection of premetastatic cancer and precancerous lesions associated with lethal phenotypes (Clinical Trial Optional) | PAR-22-131 | September 8, 2025 | R01 |
| Bioengineering Research Grants (Clinical Trial Optional) | PAR-22-243 | September 8, 2025 | R01 |
| Bioengineering Research Grants (Clinical Trial Not Allowed) | PAR-22-242 | September 8, 2025 | R01 |
| Coinfection and Cancer (Clinical Trial Not Allowed) | PAR-23-056 | November 17, 2025 | R21 |
| Co-infection and Cancer (Clinical Trial Not Allowed) | PAR-25-083 | January 8, 2026 | R21 |
| Innovative Research in Cancer Nanotechnology (IRCN; Clinical Trial Not Allowed) | PAR-23-246 | May 5, 2026 | R01 |
| Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (Clinical Trial Not Allowed) | PAR-25-153 | September 8, 2026 | R01 |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (Clinical Trial Not Allowed) | PAR-25-074 | October 15, 2026 | UH2/UH3 |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (Clinical Trial Not Allowed) | PAR-25-075 | October 15, 2026 | UH2/UH3 |
| Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (Clinical Trial Not Allowed) | PAR-24-304 | October 15, 2026 | R01 |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (Clinical Trials Optional) | PAR-25-079 | January 8, 2027 | R01 |
| NCI's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (Clinical Trial Required) | PAR-25-081 | January 8, 2027 | R01 |
| Notice of Special Interest (NOSI): Quantum Sensing Technologies in Biomedical Applications | NOT-EB-23-022 | January 27, 2027 | NOSI |
| Research Projects to Develop Oncoaging Models for Cancer Research | NOT-CA-23-092 | July 31, 2027 | NOSI |
| Bioengineering Partnerships with Industry (Clinical Trial Optional) | PAR-24-325 | September 8, 2027 | U01 |
| Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (Clinical Trial Optional) | PAR-25-175 | January 8, 2028 | R01 |
| Molecular Imaging of Inflammation in Cancer (Clinical Trial Not Allowed) | PAR-24-311 | January 8, 2028 | R01 |
DCTD Grantsmanship Resources
- Awaiting Receipt of Applications (ARAs) for Large Budget Grant
- Program Project (P01) Grant Development Guidance for Investigators Interested in DCTD Research Areas
NCI Grantsmanship Resources
- NCI-wide Funding
- NCI Office of Grants Administration
- NCI Division of Extramural Activities
- The NCI Grants Process
- Guidelines and Tools for Clinical Protocol Development
NIH Grantsmanship Resources
- NIH Parent Announcements
- Office of Extramural Research
- Grant Application Basics
- Center for Scientific Review
- Small Business Funding Opportunities
- New and Early Stage Investigator Policies